Trial ID or NCT#

NCT02448641

Status

NOT RECRUITING

Purpose

Controlled study of stereotactic, intracranial injection of SB623 cells in patients with fixed motor deficits from ischemic stroke

Official Title

A Double-Blind, Controlled Phase 2b Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke

Eligibility Criteria

Ages Eligible for Study: 18 Years to 75 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Gary K. Steinberg, MD, PhD
Cerebrovascular neurosurgeon, Moyamoya surgeon, Aneurysm neurosurgeon, Neurosurgeon
Bernard and Ronni Lacroute-William Randolph Hearst Professor in Neurosurgery and Neurosciences and Professor, by courtesy, of Neurology

Contact us to find out if this trial is right for you.

CONTACT

SPECTRUM